



**HAL**  
open science

## **PW02-012 - First clinical description of an infant with DITRA**

Linda Rossi-Semerano, Maryam Piram, Christine Chiaverini, Dominique de Ricaud, Asma Smahi, Isabelle Koné-Paut

► **To cite this version:**

Linda Rossi-Semerano, Maryam Piram, Christine Chiaverini, Dominique de Ricaud, Asma Smahi, et al.. PW02-012 - First clinical description of an infant with DITRA. *Pediatric Rheumatology*, 2013, 11 (Suppl 1), pp.A152. inserm-00881679

**HAL Id: inserm-00881679**

**<https://inserm.hal.science/inserm-00881679v1>**

Submitted on 8 Nov 2013

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



MEETING ABSTRACT

Open Access

# PW02-012 - First clinical description of an infant with DITRA

L Rossi-Semerano<sup>1\*</sup>, M Piram<sup>1</sup>, C Chiaverini<sup>2</sup>, D De Ricaud<sup>3</sup>, A Smahi<sup>4</sup>, I Koné-Paut<sup>5</sup>

From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switzerland. 22-26 May 2013

## Introduction

Interleukin-36-receptor antagonist deficiency (DITRA) is a recently described auto-inflammatory disease<sup>1</sup>, characterized by repeated flares of generalized pustular psoriasis, high fever, asthenia and systemic inflammation. This condition is caused by homozygous missense mutation in the *IL36RN* gene, encoding the interleukin-36-receptor antagonist (IL-36Ra), an anti-inflammatory cytokine. We report herein the first exhaustive clinical description of an infant with DITRA, who was successfully treated with anakinra.

## Case report

Y.M. is the first son of Tunisian consanguineous parents who developed, at two weeks of life, an erythematous and scaly eruption, with subsequent rapid evolution toward generalized pustular psoriasis. Afterwards, cutaneous flares of diffuse erythematous rash and pustules involving the whole body appeared, with a once weekly periodicity. Intense irritability was present during flares without fever. Moreover, since 1 month of age the infant presented diarrhea, dysphagia and reduced feeding rate, with failure to thrive. Laboratory tests during acute flares showed marked leukocytosis, thrombocytosis and anemia without C-reactive protein elevation. Skin biopsy and clinical presentation were consistent with pustular psoriasis, nevertheless, the patient did not respond to high-potency topical corticosteroids and retinoid acid.

As the patient presented repeated skin flares early after birth, as well as serious constitutional distress with failure to thrive, an auto-inflammatory syndrome like DIRA (interleukine-1 receptor antagonist deficiency)[2] or DITRA was considered. The hypothesis was reinforced

by parental consanguinity, and absence of skin lesions improvement under standard topical treatment. Genetic analyses showed a homozygous mutation in the *IL36RN* gene (L27P) which represents the same mutation recently described in DITRA patients[1,3]. At 6 months we started treatment with the recombinant IL-1 receptor antagonist anakinra with efficacy both on constitutional symptoms and skin involvement.

## Discussion

To the best of our knowledge, we report the first detailed clinical description of an infant with DITRA. Even if neonatal onset has been already reported[1], no detailed clinical description was provided, probably due to late diagnosis. Our clinical report brings new clinical characteristics and educational iconography. We even report, for the first time, a favorable clinical response of this disease to anakinra treatment.

## Disclosure of interest

L. Rossi-Semerano: None Declared, M. Piram: None Declared, C. Chiaverini: None Declared, D. De Ricaud: None Declared, A. Smahi: None Declared, I. Koné-Paut Grant / Research Support from: Educational and research grant from Swedish Orphan Biovitrum, Consultant for: Consultant fee from Novartis

## Authors' details

<sup>1</sup>Department of Paediatrics and Paediatric Rheumatology, Bicêtre Hospital, National Reference Centre for Auto-inflammatory Diseases, Le Kremlin-Bicêtre, France. <sup>2</sup>Service de dermatologie et centre de référence des épidermolyses bulleuses héréditaires Hôpital Archet 2 CHU de Nice, France. <sup>3</sup>Service de pédiatrie, GCS CHU-Lenval, Nice, France. <sup>4</sup>U781 INSERM, Hôpital Necker Enfants Malades, Paris, France. <sup>5</sup>Department of Paediatrics and Paediatric Rheumatology, Bicêtre Hospital, National Reference Centre for Auto-inflammatory Diseases, Le Kremlin Bicêtre, France.

Published: 8 November 2013

<sup>1</sup>Department of Paediatrics and Paediatric Rheumatology, Bicêtre Hospital, National Reference Centre for Auto-inflammatory Diseases, Le Kremlin-Bicêtre, France

Full list of author information is available at the end of the article

#### References

1. Marrakchi S, Guigue P, Renshaw BR, *et al*: **Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.** *N Engl J Med* 2011, **365**(7):620-8.
2. Aksentjevich I, Masters SL, Ferguson PJ, *et al*: **An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist.** *N Engl J Med* 2009, **360**(23):2426-2437, doi:10.1056/NEJMoa0807865.
3. Onoufriadis A, Simpson MA, Pink AE, *et al*: **Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.** *Am J Hum Genet* 2011, **89**(3):432-437.

doi:10.1186/1546-0096-11-S1-A152

**Cite this article as:** Rossi-Semerano *et al*: PW02-012 - First clinical description of an infant with DITRA. *Pediatric Rheumatology* 2013 **11** (Suppl 1):A152.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

